

Clinical Trial Protocol

Iranian Registry of Clinical Trials

28 May 2026

Comparing efficacy of Rivaroxaban versus Warfarin on carotid plaque in NVAF patients

Protocol summary

Study aim

Determining and comparing the effectiveness of Rivaroxaban and Warfarin on carotid plaque in non-valvular atrial fibrillation patients

Design

This study is a 2-3 phase clinical trial in which 60 patients are divided into two groups. People who are visited on the even days receive Rivaroxaban and people who are visited on the odd days receive Warfarin. Patients follow for 6 months. Not blind, Two arm parallel groups, No control group

Settings and conduct

Sixty patients with non-valvular atrial fibrillation referred to Farabi hospital of Kermanshah in 1397 are randomly divided into two groups. One group will receive Rivaroxaban and one group will receive Warfarin

Participants/Inclusion and exclusion criteria

Non-valvular atrial fibrillation with stroke or transient ischemic attack or IF less than 30%, Lack of kidney and liver diseases and other specific disease, Not taking Aspirin

Intervention groups

One group will receive Rivaroxaban based on GFR and one group will receive Warfarin based on GFR

Main outcome variables

Carotid plaque size, Internal and common carotid stenosis grade, Create new carotid artery plaque, Stroke.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20190729044372N1**

Registration date: **2019-09-01, 1398/06/10**

Registration timing: **registered_while_recruiting**

Last update: **2019-09-01, 1398/06/10**

Update count: **0**

Registration date

2019-09-01, 1398/06/10

Registrant information

Name

Leila Afshar hezarkhani

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 8670 5503

Email address

lafsharh@kums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-03-07, 1397/12/16

Expected recruitment end date

2019-09-07, 1398/06/16

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparing efficacy of Rivaroxaban versus Warfarin on carotid plaque in NVAF patients

Public title

Comparing efficacy of Rivaroxaban versus Warfarin on carotid plaque

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Non -valve atrial fibrillation with stroke or TIA or IF<30%

Not taking Aspirin Lack of kidney and liver diseases and other specific disease

Exclusion criteria:

Having a heart valve disorder Taking Aspirin

Age

No age limit

Gender

Both

Phase

2-3

Groups that have been masked

No information

Sample size

Target sample size: 60

Randomization (investigator's opinion)

Not randomized

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Kermanshah University of Medical Sciences

Street address

Kermanshah University of Medical Sciences Building # 2, Shahidbeheshti Ave

City

Kermanshah

Province

Kermanshah

Postal code

6715847141

Approval date

2019-01-08, 1397/10/18

Ethics committee reference number

IR.KUMS.REC.1398.183

Health conditions studied

1

Description of health condition studied

Stroke

ICD-10 code

I67.9

ICD-10 code description

Cerebrovascular disease, unspecified

Primary outcomes

1

Description

Carotid plaque size

Timepoint

Baseline and 6 months later

Method of measurement

Bilateral carotid artery color Doppler ultrasound

2

Description

Internal and common carotid stenosis grade

Timepoint

Baseline and 6 months later

Method of measurement

Bilateral carotid artery color Doppler ultrasound

3

Description

Create new carotid artery plaque

Timepoint

Baseline and 6 months later

Method of measurement

Bilateral carotid artery color Doppler ultrasound

Secondary outcomes

1

Description

Brain stroke

Timepoint

At baseline and 6 Months later

Method of measurement

Bilateral carotid artery color Doppler ultrasound

2

Description

Probability of recurrence of stroke

Timepoint

At baseline and 6 Months later

Method of measurement

Bilateral carotid artery color Doppler ultrasound

Intervention groups

1

Description

Intervention group: In this group, 30 patients are treated with Rivaroxaban based on GFR for 6 months.patients undergo Color Doppler ultrasound At baseline and after 6 months

Category

Treatment - Drugs

2

Description

Intervention group:Thirty patients in this intervention group are treated for 6 months with warfarin made by Obeidi Company based on GFR. patients undergo Color Doppler ultrasound At baseline and after 6 months

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Farabi hospital

Full name of responsible person

Leila Afsharhezarkhani

Street address

Farabi hospital, Dolatabad Blvd, Isar Square, Kermanshsh

City

Kermanshah

Province

Kermanshah

Postal code

1336616351

Phone

+98 83 3836 1046

Email

Lafsharh@kums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Kermanshah University of Medical Sciences

Full name of responsible person

Farid Najafi

Street address

Deputy of Science and Technology, Kermanshah University of Medical Sciences,Shahid Beheshti Boulevard,Kermanshah

City

Kermanshah

Province

Kermanshah

Postal code

6715847141

Phone

+98 83 3838 4185

Fax

+98 83 3837 0541

Email

farid_n32@yahoo.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Kermanshah University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Kermanshah University of Medical Sciences

Full name of responsible person

Leila Afsharhezarkhani

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Neurology

Street address

Farabi Hosital,Begining at Dolatabad Boulevard.Isar Sq

City

Kermanshah

Province

Kermanshah

Postal code

1336616351

Phone

+98 21 8670 5503

Fax

Email

Lafsharh@kums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Kermanshah University of Medical Sciences

Full name of responsible person

Leila Afsharhezarkhani

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Neurology

Street address

Farabi hospital, Dolatabad Blvd,Kermanshah

City

Kermanshah

Province

Kermanshah

Postal code
1336616351
Phone
+98 83 3836 1046
Email
Lafsharh@kums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Kermanshah University of Medical Sciences
Full name of responsible person
Leila Afsharhezarkhani
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Neurology
Street address
Farabi Hosital,Begining at Dolatabad Boulevard,Isar Sq
City
Kermanshah
Province
Kermanshah
Postal code
1336616351
Phone
+98 21 8670 5503
Fax
Email
Lafsharh@kums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

All data is shared after unidentifiable people

When the data will become available and for how long

Start of access period 6months after printing results

To whom data/document is available

Dat will be available only to researchers working in academic and scientific institutions

Under which criteria data/document could be used

For the people mentioned above there is no limit to how data will be used

From where data/document is obtainable

Leila Afsharhezarkhani,lafsharh@kums.ac.ir

What processes are involved for a request to access data/document

Contact with Leila Afsharhezarkhani via email (lafsharh@kums.ac.ir)

Comments